Reuters logo
BRIEF-Acorda to discontinue development of Dalfampridine for treatment of post-stroke walking difficulties
2016年11月21日 / 上午11点17分 / 10 个月前

BRIEF-Acorda to discontinue development of Dalfampridine for treatment of post-stroke walking difficulties

Nov 21 (Reuters) - Acorda Therapeutics Inc -

* Milestone clinical study did not show sufficient efficacy to support further development of dalfampridine to improve pswd

* To discontinue development of dalfampridine for treatment of post-stroke walking difficulties

* Plan to focus research and development resources on developing our promising late-stage parkinson’s disease therapies, CVT-301 and tozadenant

* Also plan to focus research and development resources on advancing earlier stage assets, CVT-427 in migraine, SYN120 in parkinson’s disease dementia, rHIgM22 in MS Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below